ICU Medical (NASDAQ:ICUI) executives outlined the assumptions behind the company’s 2026 outlook and provided updates on operations, product momentum, and the multi-year Smiths integration during a Q&A session at the KeyBanc Healthcare Forum. CEO Vivek Jain and CFO Brian Bonnell reiterated that the company’s guidance framework remains centered on stable hospital demand, continued pump and consumables growth, and a margin improvement plan that is expected to become more visible as integration-related cash costs roll off.
Guidance assumptions and key swing factors
Management referenced the company’s recently issued initial 2026 EBITDA guidance range of $400 million to $430 million and said the underlying macro assumptions included a stable hospital census, tariffs not worsening from levels in place at the time of the company’s February earnings call, and foreign exchange trends that have been modestly less favorable versus the euro, with the Mexican peso slightly better.
Fuel and commodity exposure after the IV solutions JV change
In response to a question about higher oil and fuel prices, management said the company’s exposure is lower than it was when ICU Medical was fully integrated in IV solutions. Jain said ICU Medical now has “only 40%” of that exposure in IV solutions following the joint venture with Otsuka Pharmaceutical, with impacts flowing differently through the income statement. He described higher oil prices as a headwind, noting the company was still working to quantify the effect and identify offsets, but emphasized the exposure is “not nearly as dramatic” as in prior years.
Growth cadence in consumables and pumps
Executives reiterated a “mid-single-digit” growth expectation for the company’s two largest businesses—consumables and systems/pumps—consistent with guidance approaches used in recent years. In consumables, Jain noted a recurring seasonal pattern of sequential decline from Q4 to Q1, and said the company expected a more pronounced effect this year due to what occurred in December. He added that February and March volumes were tracking in line with expectations and said management remained comfortable with the full-year outlook.
On pumps, Jain said the company has increased visibility because of contracts already in place and expects a meaningful installation calendar later in the year, with an anticipated back-half weighting. He also described the broader infusion pump market as being in an upgrade cycle driven by aging fleets and the practical reality that customers change systems mainly when they must—because of remediation, end-of-life issues, or obsolescence.
Management also discussed a headwind within ambulatory pumps tied to an OEM customer that has been “fading away” for three years and is expected to decline further and “ultimately go to zero this year.” Jain said the company was not surprised by this dynamic and characterized it as something the company anticipated following the acquisition that brought in the product line.
Margin outlook tied to consolidation and logistics integration
Bonnell addressed questions on gross margin progression, noting the company cited roughly 39% gross margin for 2025 and guided to around 41% for 2026. He said a “relatively clean” reference point was Q4 2025 gross margin of 40.5%.
He attributed the expected improvement to completing manufacturing facility consolidations and integrating the logistics network, with much of that work occurring in the first half of the year and benefits more visible in the second half as higher-cost transition inventory is worked down. He also cited contributions from higher plant volumes tied to growth in consumables and systems and some benefit from pricing, “mostly coming from improved LVP hardware with the new platform.” Bonnell said the company expects gross margins to improve through the year and exit 2026 above the 41% full-year average guidance.
On tariff uncertainty, Jain said conditions remained fluid and that any small near-term tariff benefits could be offset by currency moves. Management declined to add more speculation beyond acknowledging that the current environment appears temporary and subject to change.
Pipeline, software strategy, and integration progress
On product development, Jain said customer satisfaction has been high among early users of the company’s newer devices, while acknowledging typical “bumps and bruises” and software tweaks that accompany new system rollouts. He described ICU Medical’s approach as “all-in-one software” rather than “all-in-one systems,” emphasizing a unified software experience across devices.
Jain said updated Medfusion and CADD products were submitted to the FDA in July and are in a normal back-and-forth review process. He said regulatory requirements have risen, including additional testing compared with prior approvals, but described the dialogue as constructive and said agency responsiveness and timelines have not materially changed. He said the company is actively showing customers its technology roadmap while not marketing the products as approved devices.
On monetizing software, Jain said the company historically priced software low and is evaluating how to better monetize software add-ons and services alongside devices. He noted the company must find the right balance as it seeks both higher device ASPs and enhanced software value.
Turning to integration, Bonnell said ICU Medical is in the “later innings” of the Smiths integration. He highlighted manufacturing and logistics consolidation as major areas of effort and spending, with work “mostly” to be completed this year and benefits expected as transition inventory is sold down. He also said IT system integration has progressed, with the U.S. portion going live in late 2024 and EMEA going live roughly 45 days prior to the forum, with remaining work in smaller regions.
On cash flow and capital allocation, management said over $100 million per year has been spent on restructuring/integration and quality remediation, and reducing those outlays is the biggest opportunity to improve free cash flow. Bonnell noted that in the two years before the Smiths acquisition, free cash flow averaged about 100% of non-GAAP net income, and he said the company expects improvement beginning in the back half of this year, though not an immediate full return to that level.
Jain added that the company expects to reach 2x leverage by the end of the year, even if achieved “the old-fashioned way” through debt paydown. He reiterated interest in returning capital to shareholders over time, particularly given what he called a “thinly traded” security, but said the company is approaching any portfolio actions cautiously to avoid dilutive outcomes.
In closing remarks, Jain said ICU Medical’s core narrative has been consistent over the last 18 months despite tariff and macro headlines, and he emphasized management’s focus on delivering cash flow and earnings performance.
About ICU Medical (NASDAQ:ICUI)
ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.
